75 related articles for article (PubMed ID: 20623786)
1. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer.
Everitt S; Herschtal A; Callahan J; Plumridge N; Ball D; Kron T; Schneider-Kolsky M; Binns D; Hicks RJ; MacManus M
Cancer; 2010 Nov; 116(21):5030-7. PubMed ID: 20623786
[TBL] [Abstract][Full Text] [Related]
2. Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis.
Na F; Wang J; Li C; Deng L; Xue J; Lu Y
J Thorac Oncol; 2014 Jun; 9(6):834-42. PubMed ID: 24787963
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial: Should dose intensification be discontinued or should accelerated schemes remain an important area of clinical research?
Arcidiacono F; Anselmo P; Casale M; Trippa F
Radiother Oncol; 2023 Aug; 185():109688. PubMed ID: 37164107
[No Abstract] [Full Text] [Related]
4. PET Standardized Uptake Value May Influence Surgical Planning for Clinical Stage IA Non-Small Cell Lung Cancer.
Murillo AD; Kratz JR
Ann Thorac Surg; 2024 May; 117(5):1024. PubMed ID: 37369303
[No Abstract] [Full Text] [Related]
5. PET/CT in treatment response assessment in lung cancer. When should it be recommended?
Bin Essa N; Kaplar Z; Balaji N; Alduraibi A; Bomanji J; Groves AM; Lilburn DML; Navani N; Fraioli F
Nucl Med Commun; 2023 Dec; 44(12):1059-1066. PubMed ID: 37706268
[TBL] [Abstract][Full Text] [Related]
6. Evolutionary dynamics at the tumor edge reveal metabolic imaging biomarkers.
Jiménez-Sánchez J; Bosque JJ; Jiménez Londoño GA; Molina-García D; Martínez Á; Pérez-Beteta J; Ortega-Sabater C; Honguero Martínez AF; García Vicente AM; Calvo GF; Pérez-García VM
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536339
[TBL] [Abstract][Full Text] [Related]
7. Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks.
Jemaa S; Fredrickson J; Carano RAD; Nielsen T; de Crespigny A; Bengtsson T
J Digit Imaging; 2020 Aug; 33(4):888-894. PubMed ID: 32378059
[No Abstract] [Full Text] [Related]
8. Use of [
Guldbrandsen KF; Sopina L; Rasmussen TR; Fischer BM
Diagnostics (Basel); 2024 Jan; 14(2):. PubMed ID: 38275480
[TBL] [Abstract][Full Text] [Related]
9. Service Improvements and Workload Increases: Royal College of Radiologists (RCR) Re-Audit of Curative Intent Radiotherapy for Non-Small Cell Lung Cancer (NSCLC).
McAleese J; Drinkwater K;
Clin Oncol (R Coll Radiol); 2024 Jun; 36(6):e128-e136. PubMed ID: 38616447
[TBL] [Abstract][Full Text] [Related]
10. Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes.
Oxnard GR; Zhao B; Sima CS; Ginsberg MS; James LP; Lefkowitz RA; Guo P; Kris MG; Schwartz LH; Riely GJ
J Clin Oncol; 2011 Aug; 29(23):3114-9. PubMed ID: 21730273
[TBL] [Abstract][Full Text] [Related]
11. Early PET/CT scans for assessing treatment responses of non-small cell lung cancer for SBRT boost: what to do with scans from multiple scanners.
McGarry RC; Feddock J; Sinha P; Conrad G; Shelton BJ; Chen L; Arnold SM; Rinehart J
J Radiosurg SBRT; 2013; 2(4):315-323. PubMed ID: 29296374
[TBL] [Abstract][Full Text] [Related]
12. Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER).
Skougaard K; Østrup O; Guldbrandsen K; Sørensen B; Meldgaard P; Saghir Z; Gørtz P; Lonsdale MN; Frank MS; Gerke O; Rychwicka-Kielek BA; Persson G; Land LH; Schytte T; Bodtger U; Skuladottir H; Søgaard J; Nielsen SS; Rasmussen TR; Fischer BM
Clin Lung Cancer; 2020 Mar; 21(2):e61-e64. PubMed ID: 31839533
[TBL] [Abstract][Full Text] [Related]
13. Shining a Light: Unveiling Cardiac Risks Using Positron Emission Tomography Imaging in Lung Cancer Radiotherapy.
Finazzi T; Putora PM
JCO Clin Cancer Inform; 2024 Apr; 8():e2400045. PubMed ID: 38603639
[No Abstract] [Full Text] [Related]
14. Adaptive metabolic pattern biomarker for disease monitoring and staging of lung cancer with liquid biopsy.
Garcia-Algar M; Fernandez-Carrascal A; Olano-Daza A; Guerrini L; Feliu N; Parak WJ; Guimera R; Garcia-Rico E; Alvarez-Puebla RA
NPJ Precis Oncol; 2018; 2():16. PubMed ID: 30109276
[TBL] [Abstract][Full Text] [Related]
15. The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada.
Beers CA; Pond GR; Wright JR; Tsakiridis T; Okawara GS; Swaminath A
Front Oncol; 2023; 13():1210945. PubMed ID: 37681028
[TBL] [Abstract][Full Text] [Related]
16. COMP Report: CPQR technical quality control guidelines for use of positron emission tomography/computed tomography in radiation treatment planning.
Klein R; Oliver M; La Russa D; Agapito J; Gaede S; Bissonnette J; Rahmim A; Uribe C
J Appl Clin Med Phys; 2022 Dec; 23(12):e13785. PubMed ID: 36208131
[TBL] [Abstract][Full Text] [Related]
17. Reduction of inter-observer variability using MRI and CT fusion in delineating of primary tumor for radiotherapy in lung cancer with atelectasis.
Zhang H; Fu C; Fan M; Lu L; Chen Y; Liu C; Sun H; Zhao Q; Han D; Li B; Huang W
Front Oncol; 2022; 12():841771. PubMed ID: 35992838
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Pretreatment Diagnostic Assessment in Patients Treated with Stereotactic Body Radiation Therapy (SBRT) for Non-Small Cell Lung Cancer (NSCLC): Special Characteristics in the COVID Pandemic and Influence on Outcomes.
Habermann FOJ; Schmitt D; Failing T; Fischer J; Ziegler DA; Fischer LA; Alt NJ; Muster J; Donath S; Hille A; Schirmer MA; Guhlich M; El Shafie RA; Rieken S; Leu M; Dröge LH
Curr Oncol; 2022 Feb; 29(2):1080-1092. PubMed ID: 35200591
[TBL] [Abstract][Full Text] [Related]
19. Evolving target volume concepts in locally advanced non-small cell lung cancer.
Nestle U; Le Pechoux C; De Ruysscher D
Transl Lung Cancer Res; 2021 Apr; 10(4):1999-2010. PubMed ID: 34012809
[TBL] [Abstract][Full Text] [Related]
20. Validating impact of pretreatment tumor growth rate on outcome of early-stage lung cancer treated with stereotactic body radiation therapy.
Atallah S; Le LW; Bezjak A; MacRae R; Hope AJ; Pantarotto J
Thorac Cancer; 2021 Jan; 12(2):201-209. PubMed ID: 33258301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
